Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 483-490

  Furusyo, Norihiro ^a   Ogawa, Eiichi ^a   Murata, Masayuki ^a   Toyoda, Kazuhiro ^a   Ohnishi, Hachiro ^a   Eiraku, Kunimitsu ^a   Shimizu, Motohiro ^a   Harada, Yuji ^a   Mitsumoto, Fujiko ^a   Takayama, Koji ^a   Kainuma, Mosaburo ^a   Okada, Kyoko ^a   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Pegylated interferon ; Plasma trough concentrations; Ribavirin

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TELAVIC; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALLELE; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MICROBIOLOGICAL PARAMETERS; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACOKINETICS; PLASMA TROUGH CONCENTRATION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

PEGYLATED INTERFERON-Α; PLASMA TROUGH CONCENTRATIONS; RIBAVIRIN;

AGED; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84892455554     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt371     Document Type: Article

References (29)

1. SeeffLB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327:1906-11.
2. Ogawa E, Furusyo N, Kajiwara E et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
4. Furusyo N, Kajiwara E, Takahashi K et al. An association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: a project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008; 23: 1094-104.
5. FurusyoN, MurataM, OgawaEet al. Ribavirinconcentration inthelater stages of 48-week pegylated interferon-a2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother 2011; 66:1127-39.
6. Furusyo N, Ogawa E, Sudoh M et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 2012; 57: 1186-92.
7. INCIVEKTM Package Insert. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2011.
8. INCIVEKTM Canada Product Monograph. Laval, Quebec: Vertex Pharmaceuticals Incorporated, 2011.
9. INCIVO®EUSummaryof Product Characteristics. Beerse: Tibotec BVBA, 2011.
10. TELAVIC® Japan Package Insert. Osaka:Mitsubishi Tanabe Pharma, 2011.
11. Lin C, Gates CA, Rao BG et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 36784-91.
12. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
13. Hézode C, ForestierN, DusheikoGet al. Telaprevirandpeginterferonwith or without ribavirin for chronic HCV infection. NEngl J Med 2009; 360: 1839-50.
14. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
15. Kumada H, Toyota J, Okanoue Tet al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
16. Hayashi N, OkanoueT, TsubouchiHet al. Efficacyandsafety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: e134-42.
17. Furusyo N, Ogawa E, Nakamuta M et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-12.
18. Ogawa E, Furusyo N, Nakamuta M et al. Clinical milestones for the prediction of severeanemia by chronichepatitis C patients receiving telaprevirbased triple therapy. J Hepatol 2013; 59: 667-74.
19. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
20. Ogawa E, Furusyo N, Murata M et al. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57: 534-40.
21. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
22. Ogawa E, Furusyo N, Murata M et al. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia. J Viral Hepat 2013; doi:10.1111/jvh.12109.
23. Ahmed WH, Furusyo N, Zaky S et al. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia of Egyptian hepatitis Cvirus patients. World J Gastroenterol 2013; 19: 1387-95.
24. DeLongER, DeLongDM, Clarke-Pearson DL. Comparing theareasunder two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
25. Hézode C, Fontaine H, Dorival C et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
26. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365: 1014-24.
27. Chu TW, Kulkarni R, Gane EJ et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790-5.
28. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
29. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis Cvirus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77.